ICLR
ICON plc
NASDAQ · Healthcare · Medical - Diagnostics & Research · IE
$210.05
−2.52%Year over year
Reported trailing growth
- Revenue
- +1.6%
- EBITDA
- +16.2%
- EBIT
- -20.9%
- EPS
- -21.3%
- Free cash flow
- +28.8%
- Operating cash flow
- +30.6%
Forward estimates
Based on analyst estimates
- Revenue
- +0.6%
- EBITDA
- +11.4%
- EPS
- +95.2%
Three-year CAGR
- Revenue
- +2.1%
- EBITDA
- -15.5%
- EBIT
- +8.4%
- Net income
- -23.2%
- EPS
- -22.2%
- Free cash flow
- +27.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Sep 1, 2026